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Abstract 
Acquired drug resistance to targeted cancer therapies remains a significant clinical problem. 
Although mechanisms of acquired resistance of EGFR mutant non-small cell lung cancers to 
EGFR inhibitors have been identified, little is known about how resistant clones evolve during 
drug therapy. Herein, we observe that acquired resistance caused by the T790M gatekeeper 
mutation, which occurs in 50-60% of patients with acquired resistance to EGFR inhibitor therapy, 
can occur by either selection of pre-existing T790M clones or via evolution of T790M-negative 
drug tolerant cells that develop the mutation during drug treatment. Additionally, the path to 
resistance impacts the biology of the resistant clone, as those that evolved from drug tolerant 
cells have a diminished apoptotic response to third generation EGFR inhibitors that target 
T790M EGFR and can be sensitized by BCL-XL inhibitors. This observation is corroborated in 
cell cultures derived directly from resistant patient biopsies. These findings provide evidence that 
clinically relevant drug resistant cancer cells can both pre-exist and evolve from drug tolerant 
cells, and point to new therapeutic opportunities to prevent or overcome resistance in the clinic. 
 
  
Introduction 
Despite the success of targeted cancer therapies, the duration of clinical response is limited by 
the inevitable development of acquired drug resistance, as in the case of EGFR mutant non-small 
cell lung cancers (NSCLC) treated with EGFR inhibitor therapy1-3. Although molecular 
mechanisms of acquired resistance to EGFR inhibitors have been identified4-6, little is known 
about how resistant clones evolve during drug therapy. In some cases, clones with clinically 
validated genetic resistance mechanisms may exist prior to drug exposure that may simply be 
selected by treatment7-10. Alternatively, it has been hypothesized that drug tolerant (or 
“persister”) cells without bona fide resistance mechanisms may survive initial drug treatment by 
epigenetic adaptations11-13, and undergo further evolution over time to acquire validated genetic 
resistance mechanisms (Supplementary Fig. 1). Although this would have immediate 
implications for new therapeutic strategies to prevent resistance, there has not been any direct 
evidence that drug tolerant cells can undergo such evolution.  
 
To better understand the evolution of acquired resistance, we studied the development of 
resistance caused by the T790M gatekeeper mutation, which occurs in 50-60% of patients with 
acquired resistance to EGFR inhibitor therapy4.  By monitoring the development of large 
numbers of resistant clones in parallel, we were able to identify temporal patterns that reflected 
emergence of pre-existing resistant T790M clones as well as de novo acquisition of the T790M 
mutation within initially T790M-negative drug tolerant cells. Moreover, the path to resistance 
impacts the biology of the resistant clone, as those that evolved from drug tolerant cells bear 
epigenetic hallmarks of the drug tolerant state and have a diminished apoptotic response to third 
generation EGFR inhibitors that target T790M EGFR. These findings provide evidence that drug 
resistant cancer cells bearing the identical clinically relevant genetic resistance mechanism can 
both pre-exist and evolve from drug tolerant cells, and suggest that cancer cells that survive 
initial therapy may serve as an important reservoir from which acquired resistance can emerge in 
the clinic. 
 
Results 
Gefitinib resistant PC9 cells that harbor T790M have differential apoptotic response to third 
generation EGFR inhibitor treatment 
We previously cultured sensitive EGFR mutant NSCLC PC9 cells in escalating concentrations of 
the EGFR inhibitor, gefitinib, until resistant clones emerged14. Notably, in two resistant cell lines, 
PC9-GR2 and PC9-GR3, there was a marked difference in the time required to develop 
resistance, with the GR2 and GR3 lines developing in 6 and 24 weeks, respectively (Fig. 1a). 
Treatment with the third generation irreversible EGFR inhibitor WZ400215 suppressed EGFR 
phosphorylation and downstream MEK and PI3K signaling and induced cell cycle arrest in both 
resistant cell lines (Supplementary Fig. 2a-c). However, WZ4002 induced robust mitochondrial 
depolarization and subsequent apoptosis only in the PC9-GR2 cells (Supplementary Fig. 2d, Fig. 
1b). Analysis of the expression of BCL-2 family genes, which regulate the mitochondrial 
apoptotic response induced by MEK/ERK and PI3K/AKT signaling pathways16, revealed that 
PC9-GR3 cells had diminished upregulation of BIM (Supplementary Fig 2e, f), a key mediator 
of apoptosis in EGFR mutant NSCLC17-20. Similarly, induction of BIM protein levels after drug 
treatment were significantly lower in PC9-GR3 cells compared with PC9-GR2 and parental cells 
(Supplementary Fig. 2g). Consistent with the differential levels of apoptosis following treatment 
with WZ4002, treatment led to regression of PC9-GR2 but not GR3 cells in vitro (Fig. 1c, 
Supplementary Fig. 2h) and xenograft tumors in vivo despite comparable inhibition of EGFR 
and ERK phosphorylation (Fig. 1d, Supplementary Fig. 3a).  
 
Early emerging T790M resistant clones derive from pre-existing T790M cells 
The variable time to resistance led us to question whether the GR2 and GR3 cells may have 
developed T790M via different mechanisms (i.e. pre-existing versus drug tolerant evolution 
(Supplementary Fig. 1)). To explore this possibility, we cultured over 1,200 small pools (~5,000 
cells each) of parental PC9 cells in the presence of gefitinib and monitored for emergence of 
resistant clones. After two weeks of drug exposure, 5-10% of the wells contained a rapidly 
growing resistant colony (Fig. 2a), whereas the other wells contained a small number of 
surviving drug tolerant cells similar to those described previously by Settleman and colleagues11. 
Allele specific quantitative PCR revealed that all “early” resistant colonies examined (N=50) 
harbored the T790M mutation (Supplementary Fig. 4a), and all were sensitive to WZ4002 but 
not gefitinib (Fig. 2b). Treatment of PC9 pools with WZ4002 yielded drug tolerant cells but 
completely suppressed emergence of the early T790M colonies (Fig. 2c). Conversely, treatment 
of PC9 pools with gefitinib + the IGFR inhibitor NVP-AEW541, which was previously shown to 
abrogate the survival of PC9 drug tolerant cells11, eliminated drug tolerant cells without affecting 
the emergence of early T790M resistant clones. These results demonstrate that the early T790M 
resistant clones emerged independently from drug tolerant cells.  
 
Direct detection of genetically distinct rare sub-populations using currently available standard 
next-generation sequencing is limited to allelic frequencies of approximately 0.1%21, whereas 
droplet digital PCR has a sensitivity of 0.01-0.005%22. In our PC9 parental cell line, we 
estimated that approximately 1 out of 25,000-50,000 cells harbor a T790M allele prior to 
treatment (see Methods for calculation). Because PC9 cells carry 8-10 copies of EGFR 
(Supplementary Fig. 4b), and only one T790M allele is required to confer resistance 
(Supplementary Fig. 4c-d), direct detection of the pre-existing T790M clones in our parental PC9 
population would necessitate a sensitivity at least an order of magnitude beyond what is routinely 
achievable.  
 
To overcome these limitations, Stegmeier and colleagues recently reported a high-complexity 
DNA barcode library (ClonTracer) designed to track the evolution of pre-existing resistant 
clones too rare to be detected by direct approaches8. In this system, when a population of 
barcoded cells is made resistant to drug, enrichment of a shared set of barcodes between multiple 
replicates indicates emergence of pre-existing resistant clones. We utilized the ClonTracer 
lentiviral barcode library to determine whether the early resistant T790M clones were derived 
from cells with pre-existing T790M mutation. We transduced 1-2 million PC9 cells with the 
lentiviral Clontracer library, expanded the cells and split the cells (CT-A) into multiple biological 
replicates with approximately 10-fold representation of barcode complexity (Supplementary Fig. 
5a). Cells were treated with 300 nM gefitinib, and consistent with our prior experiments, rapidly 
proliferating early resistant clones were observed. These clones were T790M positive 
(Supplementary Fig. 5b), and we observed a highly consistent number of unique barcodes 
enriched in each replicate (Fig. 2d, Supplementary Fig. 5c). Approximately 90% of enriched 
barcodes in each sample were shared by at least two other replicates and over 50% were shared 
by all five replicates (Fig. 2e, Supplementary Fig. 5d). Notably, the most highly shared barcodes 
were also the most highly enriched. We repeated the entire experiment with two additional, 
independently barcoded PC9 populations (CT-B and CT-C) that yielded the same results (Fig 2e, 
Supplementary Fig. 5b-d). These results confirm that the early resistant T790M clones were 
derived from pre-existing T790M mutant cells that were selected during gefitinib treatment. 
         
Late emerging T790M resistant clones derive from drug tolerant cells 
To determine whether T790M could also evolve during treatment from initially T790M-negative 
drug tolerant cells, we cultured 16 PC9 drug tolerant cell pools with no evidence of early 
resistant clones in the presence of gefitinib until they had reached numbers sufficient for 
genotyping and drug sensitivity testing, which required 12-16 weeks. These pools remained 
partially resistant to both gefitinib and WZ4002, and T790M allele-specific PCR was negative, 
indicating non-T790M mediated resistance (Fig. 3a, Supplementary Fig. 6a). These cells were 
further cultured in gefitinib until fully resistant (20-40 weeks cumulative drug exposure) and five 
of the 16 resistant pools acquired T790M and demonstrated increased sensitivity to WZ4002 (Fig. 
3a, Supplementary Fig. 6b). To gain a better understanding of the kinetics of evolution of T790M 
resistance in these cells, we examined additional intermediate time points during the 
development of the original PC9-GR3 resistant line and several of the late T790M clones. For 
the PC9-GR3 line, T790M was first detected at 22 weeks, at a fraction of 6% of the total cell 
population, and within one month had overtaken the population as the dominant clone 
(Supplementary Fig. 6c-d, Supplementary Fig. 4d). In the other three cases examined, a minority 
T790M clone was observed at 34, 43 and 47 weeks, and by one month later had overtaken the 
population as the dominant clone (Supplementary Fig. 6d). Thus, these results suggest that the 
T790M resistance mutation can develop de novo in drug tolerant cells during the course of 
prolonged exposure to EGFR inhibition. 
 Resistant cells that remained T790M-negative were subjected to clinical multiplexed genetic 
analysis that assessed for single nucleotide variants and insertions/deletions in 39 cancer-related 
genes23.  Notably, these T790M-negative resistant cells were found to have acquired mutations in 
NRAS, KRAS, BRAF and RET (Supplementary Table 1), albeit at low allele frequencies 
suggesting mixed clonal populations. We did not observe MET or HER2 amplification, and one 
resistant line had low-level KRAS amplification in addition to a KRAS mutation (Supplementary 
Fig. 7a) in addition to a KRAS mutation. Although some of these mutations have been 
previously observed in PC9 cells and in resistant EGFR mutant NSCLC tumors by others24,25, the 
significance of these particular mutations driving resistance in the clinic is unclear. Nonetheless, 
these results suggest that drug tolerant cells have the potential to develop both T790M and non-
T790M mechanisms of resistance, which may contribute to the heterogeneity of acquired 
resistance observed in the clinic4,26.  
 
To further convince ourselves that T790M could evolve during treatment from initially T790M-
negative drug tolerant cells, we established PC9 sub-clones derived from single cells to eliminate 
pre-existing T790M cells. Indeed, in ten independent clones derived from single cells, no early 
T790M colonies emerged after two weeks of gefitinib treatment (Supplementary Fig. 8a) in 
contrast to the parental PC9 cells which harbored pre-existing T790M cells (Fig. 2a). We then 
cultured 14 pools (5,000 cells each) from single cell-derived sub-clone A (Supplementary Fig. 
8a) in gefitinib up to 40 weeks until fully resistant cells emerged. Eight acquired T790M and six 
remained T790M-negative (Fig. 3b, Supplementary Fig. 8b). Similarly, three additional clones 
(B-D) were cultured in gefitinib for several months, and all developed T790M clones (data not 
shown). To provide statistical evidence that these late T790M clones did not derive from 
undetected pre-existing T790M cells, we spiked single RFP-labeled T790M PC9 cells into pools 
of unlabeled sub-clones A-D (5,000 cells), and measured the kinetics of emergence of the 
resistant clone. As shown in Supplementary Figure 8c , over a ten week time period, all resistant 
clones were derived from RFP-positive T790M cells, with the majority emerging within the first 
two weeks. From this, we derived a cumulative density function (CDF) describing the 
probability of detecting the emergence of pre-existing T790M resistant cells as a function of time 
(Supplementary Fig. 8d-e). Since none of the single cell-derived sub-clones gave rise to T790M 
clones at 2 weeks (Supplementary Fig. 8a), the CDF determines that the probability that the late 
emerging T790M clones in clones A-D derived from undetected pre-existing T790M cells is 
0.006 (see Supplementary Fig. 8 legend for calculation). Taken together, these results confirm 
that T790M acquired resistance can evolve from initially T790M-negative drug tolerant cells. 
 
Considering the time scale and cell population sizes of our experiments, we were initially 
surprised that the T790M mutation could arise in these drug tolerant cells. Taking into account 
reasonable estimates of mutation and cell division rates, we mathematically modeled de novo 
acquisition of T790M in drug tolerant cells. We applied a simple branching model, similar to 
Chmielecki et al.27, estimating the birth rate of drug tolerant cells calculated from previously 
reported single cell imaging experiments of PC9 cells treated with erlotinib28. The growth rate 
and the initial population size of the drug tolerant PC9 cells were determined by experimentally 
measuring the proliferation of drug tolerant PC9 cell pools over time (N = 300, Supplementary 
Fig. 9a). We both solved analytically (SI) and simulated this model, and there was very close 
agreement between the results (Supplementary Fig 9b). In Figure 3c, we display the fraction of 
drug tolerant pools predicted to acquire T790M by 16 weeks of gefitinib treatment for a range of 
values of mutation and division rates.  This fraction grows linearly with the initial population 
size, division and mutation rates, and exponentially with the growth rate and time. Additionally, 
we calculated the fraction of drug tolerant pools predicted to acquire T790M as a function of 
time using a reasonable set of parameters (Fig. 3d). The mathematical model did predict 
emergence of T790M over a time period corresponding to several months. To assess the model 
experimentally, we treated 484 pools of drug tolerant 5000 PC9 cells derived from the single-cell 
clones with gefitinib for 16 weeks at which point 203 had reached sufficient numbers to 
genotype (Supplementary Fig. 9b). Three were found to be T790M positive (1.5%), which is in 
remarkable agreement with the modeling results.  
 
To examine whether T790M can evolve from drug tolerant cells in other EGFR mutant NSCLC 
models, we examined MGH119 cells that were previously derived in our laboratory from a 
treatment naïve EGFR mutant NSCLC patient14. MGH119 cells were cultured in gefitinib until 
resistant, and two independent T790M resistant lines (GR1, GR2) developed after 5-6 months. 
To determine if T790M cells pre-exist in this model, we treated MGH119 cell pools with 
gefitinib for three weeks, but no early resistant colonies were observed (Supplementary Fig. 10a). 
In contrast, when we simulated the presence of pre-existing T790M cells by introducing RFP-
labeled MGH119-GR1 cells into MGH119 parental cells, emerging gefitinib resistant RFP-
positive colonies were detectable starting at 2-3 weeks (Supplementary Fig 108b). At 10 weeks, 
only RFP-positive resistant clones were observed. These results suggest that the MGH119 cell 
line does not harbor pre-existing T790M cells, and that the MGH119-GR1 and GR2 resistant 
cells arose from drug tolerant cells by acquiring T790M during drug treatment. 
 Late T790M resistant cells bear hallmarks of evolving from drug tolerant state 
We next sought to determine if late T790M resistant cells exhibited molecular evidence of 
having evolved from the drug tolerant state, using RNA-Seq to compared the transcriptional 
profiles of PC9 drug tolerant cells with PC9-GR3, PC9-GR2 and PC9 parental cells 
(Supplementary Fig. 11a). Principal component analysis of global expressed mRNA transcripts 
at baseline and after EGFR inhibitor treatment revealed that four distinct clusters, The late 
T790M PC9-GR3 cells clustered with drug tolerant cells, and the T790M PC9-GR2 cells 
clustered with the parental PC9 cells (Fig. 3e). Whereas as PC1 primarily differentiated between 
baseline and drug treated samples, PC2 segregated late T790M PC9-GR3 and drug tolerant cells 
from early T790M PC9-GR2 and parental cells (Supplementary Fig. 11b). Gene set enrichment 
analysis revealed upregulation of genes related to epithelial-to-mesenchymal transformation in 
drug tolerant/PC9-GR3 cells relative to parental PC9-GR2/parental cells, which has been linked 
to acquired resistance to EGFR inhibitor therapy in the clinic4. Taken together, these results 
demonstrate that the late emerging T790M PC9-GR3 cells share a transcriptional profile most 
similar to drug tolerant cells. This further supports the model that the late T790M resistant cells 
evolved from drug tolerant cells (Fig. 3f) and suggests that molecular features of the drug 
tolerant state may be maintained even after acquisition of T790M. 
 
Late T790M resistant cells have decreased apoptotic response to 3rd generation EGFR inhibitor 
therapy 
By definition, evasion of drug-induced apoptosis in the presence of EGFR inhibition is a 
characteristic feature of drug tolerant cells (Supplementary Fig. 12a-b). Since late T790M 
resistant cells evolved from drug tolerant cells and continue to share a similar mRNA expression 
profile (Fig. 3e), we reasoned that they might also exhibit reduced apoptotic sensitivity to 
subsequent EGFR inhibition. Similar to PC9-GR3 cells (Fig. 1b), late T790M resistant PC9 
clones that emerged from drug tolerant cells had a reduced apoptotic response to WZ4002 
treatment compared to early T790M resistant clones that derived from pre-existing cells (Fig. 4a). 
Moreover, when we induced expression of T790M EGFR in drug tolerant cells, the T790M 
resistant clones that grew out had reduced apoptotic sensitivity to WZ4002 (Supplementary Fig. 
13a-b). MGH119-GR1 and GR2 cells, which developed T790M late consistent with evolution 
from drug tolerant cells, also exhibited reduced apoptotic response to WZ4002 relative to 
MGH119 parental cells and MGH119 cells in which we introduced T790M EGFR by lentiviral 
expression (Fig. 4b, Supplementary Fig. 13c). These results demonstrate that T790M resistant 
cells that evolve during drug treatment have reduced dependence on EGFR activation for 
survival compared to pre-existing T790M cells, consistent with the notion that these cells 
evolved from drug tolerant cells that are by definition less sensitive to EGFR inhibition than 
those that underwent apoptosis upon initial treatment.  
 
To investigate the clinical implications of the laboratory-derived acquired resistance models, we 
examined cell lines derived from EGFR mutant NSCLC patient tumors at the time of clinical 
progression due to T790M acquired resistance14 (Supplementary Table 2). Three cells lines were 
exquisitely sensitive to WZ4002, whereas four had a diminished apoptotic response and 
increased in vitro survival (Fig. 4c-d). In vivo sensitivity of MGH141 and MGH134 xenograft 
tumors mirrored the in vitro response, with the low apoptosis MGH134 cell line xenografts 
failing to undergo tumor regression (Fig. 4e) despite suppression of EGFR and ERK signaling 
(Supplementary Fig. 3b). Intriguingly, the least sensitive cell lines corresponded to patients with 
the longest duration of response to first line EGFR inhibitor therapy prior to development of drug 
resistance (Fig. 4f), raising the possibility that these low-apoptotic resistant cells evolved from 
drug tolerant cells.  
 
These results raise the possibility that resistant cancers in which T790M originates during 
therapy may have a reduced apoptotic sensitivity to third generation EGFR inhibitors that are 
currently being evaluated in the clinic29-31. Therefore, we sought to identify therapeutic strategies 
that could enhance the apoptotic response to third generation EGFR inhibitors. Recently, we 
reported a drug screening strategy for identifying effective drug combinations for cancers with 
acquired resistance to targeted therapies14. Because this screen was focused on overcoming 
bypass resistance mechanisms, effective drug combinations were identified based on a shift in 
GI50. However, we noted that the decrease in apoptosis in our models was most clearly reflected 
by a change in Emax (Supplementary Fig. 14). Therefore we reanalyzed the screen data for three 
low apoptosis T790M patient-derived cell lines (MGH134, MGH157, MGH125) to identify 
drugs that increased Emax when combined with WZ4002. Additionally, we performed the 
identical drug screen on PC9-GR3 cells also using WZ4002 as the anchor. Of the top scoring 
compounds for each cell line, the only one common to all three was the BCL-XL/BCL-2 
inhibitor ABT263/navitoclax (Fig. 5a). Interestingly, prior laboratory studies have demonstrated 
that BCL-XL/BCL-2 inhibitors can enhance the apoptotic activity of targeted therapies that 
induce apoptosis by inducing BIM17,32,33, presumably by decreasing the capacity for BCL-XL to  
neutralize BIM. The combination of WZ4002 and navitoclax induced a robust apoptotic response 
in low apoptosis T790M patient-derived cell lines (Fig. 5b) and in vitro generated T790M 
resistant cell lines (Fig. 5c). In vivo, WZ4002 + navitoclax induced dramatic regression of 
MGH134 and PC9-GR3 xenograft tumors (Fig. 5d). Thus combining navitoclax with third 
generation EGFR inhibitors may be an effective strategy for T790M resistant cancers with 
decreased apoptotic response to EGFR inhibition. Indeed, the combination of AZD9291 and 
navitoclax will be tested in an upcoming clinical trial of EGFR NSCLC with acquired resistance 
to first line EGFR inhibitor therapy (NCT02520778). 
 
Discussion 
It is now well appreciated that significant genetic heterogeneity exists between cancer cell clones 
within a tumor34. While activating driver alterations such as the characteristic EGFR L858R 
mutation or exon 19 deletion are present in virtually every cell within an EGFR NSCLC tumor, 
the repertoire of accompanying mutations may vary34,35. While pre-existing intertumoral 
heterogeneity has been shown to influence treatment response and the development of acquired 
resistance to targeted therapy in some contexts36, there has been surprisingly little direct clinical 
evidence supporting either emergence of pre-existing resistant clones or de novo evolution as the 
predominant mechanisms of acquired resistance in lung cancer. Several studies have reported the 
detection of low frequency T790M positive clones in pre-treatment clinical specimen9,37, 
however doubts have been raised as to whether the majority of these may be simply sequencing 
artifacts related to tissue fixation10. 
 
Our results provide proof of principle that T790M clones not only emerge from selection of pre-
existing clones but also can emerge from initially T790M-negative drug tolerant cells. Survival 
of drug tolerant cancer cells may be facilitated by cell autonomous features such as altered 
epigenetic states11,38 and feedback activation of alternate survival pathways12 as well as external 
stimuli from the microenvironment13,39. While these mechanisms may be sufficient to prevent 
apoptosis and promote support survival of drug tolerant cells, they may not fully recapitulate the 
optimal oncogenic signaling provided by EGFR. Subsequent acquisition of T790M likely 
provides an additional fitness advantage in the presence of drug. Thus drug tolerant cells that are 
capable of surviving initial drug therapy may provide a reservoir of cells from which genetic 
mechanisms of acquired resistance can evolve. Such resistant clones may continue to share 
molecular features of the drug tolerant cells (Fig. 3e-f), leading to a diminished apoptotic 
response to subsequent therapies. 
 
We believe that these findings have important clinical implications. These results provide a 
rationale for investigation of novel strategies for therapeutic targeting of drug tolerant cells 
before acquisition of genetic mechanisms of resistance in order to prevent or delay the evolution 
of acquired resistance and improve patient outcomes. We speculate that the majority of cancer 
cells that initially survive following therapy likely do not have bona fide resistant mechanisms 
(e.g., T790M), but more closely resemble a drug tolerant state. Since we now know that these 
drug tolerant cells can develop genetic mechanisms of resistance over time, we need to develop 
therapeutic approaches that kill this reservoir of drug tolerant cells that fail to undergo apoptosis. 
If successful, this should lead to more complete clinical remissions. Such treatment strategies 
will also need to integrate approaches that target the rare pre-existing bona fide resistant clones. 
We are hopeful that innovative approaches such as these will lead to markedly improved patient 
outcomes.  
 
Figure Legends: 
 
Figure 1. Variable sensitivity of T790M resistant PC9 cell lines to third generation EGFR 
inhibition. 
a, PC9 parental cells were cultured in escalating concentrations of gefitinib as tolerated until 
fully resistant, which was defined as lack of inhibitory effect of drug on cell proliferation. PC9-
GR2 resistant cells developed resistance more rapidly than PC9-GR3 cells. 
b, PC9-GR3 cells have decreased apoptotic response to the third generation EGFR inhibitor 
WZ4002 compared to PC9-GR2 and parental cells. Cells were treated with 1 µM gefitinib (G), 1 
µM WZ4002 (W) or vehicle (V) for 72 hours and apoptosis determined by annexin staining (data 
shown are mean and standard error of four independent experiments). 
c, PC9-GR3 cells exhibit a net proliferative response to WZ4002 in vitro. Cells were treated with 
1 µM gefitinib (GEF), 1µM WZ4002 (WZ) or vehicle (VEH) and cell proliferation was 
determined by CellTiter-Glo assay (mean and standard error of 4-5 independent experiments). 
d, WZ4002 induces tumor regression of PC9-GR2 but not PC9-GR3 sub-cutaneous xenograft 
tumors.  Mice bearing PC9-GR2 or PC9-GR3 subcutaneous xenograft tumors were treated with 
50 mg/kg/day WZ4002. (PC9-GR2 - control (N=8), WZ (N=8); PC9-GR3 - control (N=8), WZ 
(N=8)) 
 
Figure 2. Early T790M acquired resistance results from selection of pre-existing T790M 
clones. 
a, Rapid emergence of gefitinib resistant PC9 clones. PC9 parental cell pools were treated with 
300 nM gefitinib for two weeks and cell viability was determined by CellTiter-Glo assay. 7% of 
wells contained a rapidly proliferating resistant colony, while the remaining wells contained a 
small number of drug tolerant cells (inset). Each bar represents one well; data shown are 
combined from two independent experiments and are normalized to the mean viability of drug 
tolerant wells.  
b, Early gefitinib resistant clones are sensitive to WZ4002. Upper panel, 50 early resistant clones 
were treated with gefitinib (GEF) or WZ4002 (WZ) for 72 hours and cell viability determined. 
Inset shows dose response of PC9 parental cells. Lower panel, cell viability of each early 
resistant T790M clone after treatment with 1 µM WZ4002 or gefitinib relative to vehicle control. 
Diagonal axis indicates equal sensitivity to both drugs (e.g. non-T790M), whereas sensitivity to 
WZ4002 but not gefitinib (lower right quadrant) indicates T790M. Parental cells are sensitive to 
both drugs and are shown for comparison. 
c, Early gefitinib resistant cells are distinct from drug tolerant cells. PC9 cell pools (5,000 cells) 
were treated with 1 µM WZ4002 or 300 nM gefitinib + 500 nM NVP-AEW541 for two weeks 
and cell viability determined. WZ4002 suppressed emergence of early T790M resistant clones, 
whereas addition of AEW541 to gefitinib had no impact on emergence of early T790M clones 
despite elimination of drug tolerant cells. 
d, ClonTracer barcoding technology demonstrates the pre-existence of early resistant gefitinib-
resistant clones in the PC9 cell line, which were confirmed to harbor the T790M mutation 
(Supplementary Fig. 5b). The barcode distribution (fraction of each unique barcode in the total 
barcode reads) of one representative replicate each from CT-A barcoded cells treated with 
vehicle and gefitinib. The x-axes of the histograms are identical; each bar represents one unique 
barcode.  
e, Percentage of enriched barcodes in each replicate that were also found in other replicates (1-5) 
for each independently barcoded experiment (CT-A,B,C). Colors denote the number of other 
replicates in which the barcodes were identified. 
 
Figure 3. Late emerging T790M acquired resistance results from evolution of initially 
T790M-negative drug tolerant cells. 
a, PC9 cell pools comprised of only drug tolerant cells were cultured in gefitinib until fully 
resistant. After 12 weeks of drug treatment, cells were partially resistant to both gefitinib and 
WZ4002 and negative for T790M by allele-specific PCR. After an additional 10-30 weeks, all 
were fully resistant to gefitinib and 5 of 16 had acquired T790M. 
b, Late T790M resistant clones emerge from single cell-derived clone A after prolonged 
culturing in gefitinib. 
c, Mathematical modeling of the acquisition of the T790M mutation within drug tolerant PC9 
populations displaying the predicted frequency of PC9 cell pools (starting population 5000) 
developing a T790M mutation during 16 weeks of drug treatment as a function of mutational rate 
and cell division rate. Frequency values were calculated from the analytical solution and are 
represented as log10 of the percentage of wells predicted to develop T790M. Parameters that 
predict the experimentally observed 1.5% of wells acquiring T790M by 16 weeks are depicted 
by the solid (mean) and dotted (95% confidence interval) lines. The scale of the x-axis 
corresponds to a division rate of once very two weeks (low) to the rate of PC9 cells in the 
absence of drug (high).  
d, Predicted frequency of acquiring T790M as a function of time calculated from the analytical 
solution of the model (black line is mean value, gray shaded area represents calculated standard 
deviation). Parameters for drug tolerant cells: initial population size N0=150, birth rate b=0.0162, 
death rate d=0.015, mutation rate µ=7.7x10-10. The birth and death rates of T790M mutant cells 
are br=0.04 and dr=0.0015, respectively28.   
e, Principal component analysis of global transcriptional profiles of PC9 parental, drug tolerant 
(selected in drug for 2 weeks; GT = gefitinib tolerant, WT = WZ4002 tolerant), early T790M 
PC9-GR2 and late T790M PC9-GR3 cells determined by RNA-Seq. Prior to harvesting RNA, 
cells were treated with vehicle or 1µM gefitinib (GEF) or WZ4002 (WZ) for 24 hours. PC9-GR3 
cells cluster with drug tolerant cells. 
f, Model for development of T790M acquired resistance from pre-existing T790M cells as well 
as evolution of initially T790M-negative drug tolerant cells. 
 
Figure 4. Late evolving T790M acquired resistance is associated with decreased apoptotic 
sensitivity to third generation EGFR inhibition. 
a, Late T790M PC9 resistant clones that emerged from parental and single cell-derived clones 
have decreased apoptotic response to WZ4002 compared to early resistant T790M clones that 
arose from pre-existing T790M cells. (Each dot represents an independent resistant clone, data 
shown are mean of 4-6 independent experiments. PAR = PC9 parental cells). 
b, Gefitinib resistant MGH119 EGFR mutant NSCLC cells (GR1, GR2) that emerged after 
culturing in gefitinib for 5-6 months have decreased apoptotic response compared to parental 
cells (PAR) and MGH119-pTREX-T790M cells that were generated by introducing a Tet-
inducible EGFR Del19/T790M construct. Expression of EGFR Del19/T790M was induced prior 
to the experiment by culturing in the presence of doxycycline. Cells were treated with 1 µM 
gefitinib (G), WZ4002 (W) or vehicle (V). (Data shown are mean and standard error of 3-6 
independent experiments.) 
c, Patient-derived T790M EGFR mutant NSCLC cell lines have variable apoptotic response to 
WZ4002. (Data shown are mean and standard error of 4-7 independent experiments.) 
d, Patient-derived cell lines with decreased apoptotic response have increased long term cell 
viability in the presence of WZ4002. Cells were treated with vehicle (open symbols) or 1 µM 
WZ4002 (closed symbols) and cell number determined by nuclear counting by high content 
imaging (mean and standard error of four replicates). 
e, In vivo response of T790M cell line xenografts of WZ4002 mirrors in vitro apoptotic 
sensitivity. MGH134 and MGH141 sub-cutaneous xenograft tumors were treated with 50 
mg/kg/day WZ4002 (closed squares), which suppressed growth of both xenograft tumor models 
compared with controls (open squares) but only induced regression of MGH141 tumors. 
(MGH134 - control (N=8), WZ  (N=10); MGH141 - control (N=7), WZ (N=8)) 
f, Apoptotic sensitivity of patient-derived cell lines inversely correlates with duration of response 
of patient to first line EGFR inhibitor therapy. High apoptosis cell lines (MGH121, 164, 141); 
low apoptosis cell lines (MGH134, 157, 125, 138). Time to progression (TTP) was determined 
by time from initiation of therapy to first restaging scan showing definitive progression of 
disease. Statistical significance was calculated using the Mann-Whitney U test. 
 
Figure 5. Navitoclax enhances apoptotic response of late T790M resistant cells with 
decreased sensitivity to third generation EGFR inhibition. 
a, Top drug hits from a combination drug screen14 that led to an enhancement of Emax when 
combined with WZ4002 in at least two of four T790M resistant cell lines screened. The response 
of MGH134 cells to ABT263 is shown as an example. 
b, The combination of navitoclax (ABT263) and WZ4002 induces apoptosis in patient-derived 
T790M cell lines that have poor response to WZ4002 alone. (Data shown are mean and standard 
error of 4-7 independent experiments). 
c, In vitro derived late T790M gefitinib resistant cell lines have increased apoptotic response to 
the combination of navitoclax and WZ4002 (Data shown are mean and standard error of 4-5 
independent experiments). 
d, Mice bearing MGH134 and PC9-GR3 subcutaneous xenograft tumors were treated with 100 
mg/kg/day navitoclax and/or 50 mg/kg/day WZ4002. Robust tumor regression was observed 
only for the combination. (MGH134 N=8 control, 10 WZ, 8 ABT, 7 WZ+ABT; PC9-GR3 N=8 
control, 8 WZ, 7 ABT, 7 WZ+ABT. Control and WZ data from Figures 1D and 3D are shown 
for comparison.)  
Supplementary Figure Legends: 
 
Supplementary Figure 1. Schematic depicting development of acquired resistance by either 
the emergence of a pre-existing resistant clone (e.g. T790M) versus evolution of a drug 
tolerant intermediate that acquires the genetic resistance mechanism during the course of 
drug treatment.  
 
Supplementary Figure 2. WZ4002 inhibits EGFR phosphorylation and downstream MEK 
and PI3K signaling in PC9, GR2 and GR3 cells, but fails to up-regulate BIM and induce 
mitochondrial depolarization in PC9-GR3 cells. a, Cells were treated with 1 µM gefitinib (G), 
WZ4002 (W) or vehicle (V) for 24 hours and lysates harvested for western blotting. b, 
Transcriptional outputs of MEK/ERK (DUSP6, SPRY4) and PI3K/AKT signaling (HER3, 
DAPK1) are modulated equally by WZ4002 in PC9, GR2 and GR3 cells. Cell were treated with 
1 µM WZ4002 or vehicle for 24 hours. Gene transcript levels were determined by quantitative 
RT-PCR and normalized to ACTIN. Values shown are fold difference in transcript level after 
WZ4002 treatment relative to vehicle control. c, Cells were treated with 1 µM WZ4002 for 18 
hours and cell cycle populations were determined by propidium iodide staining. There was no 
statistical difference between the % increase in cells in G1 or % decrease in cells in S phase after 
WZ4002 treatment between any of the three cell lines. 
d, Cells were treated with 1 µM gefitinib (G), WZ4002 (W) or vehicle (V) in the presence of the 
pan-caspase inhibitor 10 µM QVD-Oph in triplicate. After 48 hours, cells were harvested and 
stained with JC-1 (Life Technologies) and analyzed by flow cytometry. e, Cells were treated 
with 1 µM WZ4002 for 24 hours in duplicate and RNA harvested for RNA-Seq analysis. Values 
shown are log2 fold change after WZ treatment. f, BIM mRNA transcript levels were quantified 
by quantitative RT-PCR following treatment with 1 µM WZ4002 for 24 hours and normalized to 
GAPDH. Values shown are mean and standard error of three independent experiments. g, Cells 
were treated with 1 µM gefitinib (G), WZ4002 (W) or vehicle (V) and harvested for western 
blotting. Band intensities were quantitated by densitometric analysis and normalized to vehicle 
control; values shown are mean and standard error of four independent experiments. h, Induction 
of apoptosis is necessary for cytotoxic response of PC9-GR2 cells to WZ4002 in vitro. Cells 
were treated with vehicle or 1 µM WZ4002 in the presence or absence of 20 µM QVD-Oph 
(pan-caspase inhibitor). Apoptosis was determined by annexin staining after 72 hours. Cell 
proliferation was determined by CellTiter-Glo assay. Blocking the apoptotic response in PC9-
GR2 cells resulted in cytostatic response similar to PC9-GR3 cells (see Fig. 1c). 
 
Supplementary Figure 3. Inhibition of EGFR and ERK phosphorylation after WZ4002 
treatment in xenograft tumors. Mice were treated with 50 mg/kg/day WZ4002 daily and 
tumors were harvested 3 hours after the day 3 dose for western blot analysis. Phosphorylated 
EGFR and phosphorylated ERK1/2 band intensities were quantified by densitometric analysis, 
and each data point is the relative phospho-protein abundance from an individual mouse. 
Asterisks indicate that statistically significant decreases in EGFR and ERK phosphorylation were 
observed after drug treatment for all models. There were no significant differences in 
phosphorylation levels in drug treated tumors between a, GR2 versus GR3 and b, MGH141 
versus MGH134 models. 
 
Supplementary Figure 4. Characterization of T790M alleles in gefitinib resistant PC9 cells. 
a, T790M allele specific quantitative PCR performed on genomic DNA isolated from 50 early 
gefitinib resistant clones revealed that all harbor the T790M mutation. Values shown are the 
difference in Cp values between the T790M specific probe and deletion 19 control. b, EGFR is 
amplified in PC9 cells. Relative EGFR amplification assessed by quantitative PCR on genomic 
DNA. Copy number relative to LINE1 and chromosome 7 was calculated after normalization to 
MGH1075 (stromal fibroblast DNA) diploid control. c, T790M allelic abundance in PC9-GR2 
and PC9-GR3 cells as determined by droplet digital PCR and next generation sequencing 
corresponds to one mutant allele per 8-10 total EGFR alleles. d, Single cell clones of PC9-GR2 
and PC9-GR3 lines were established and assayed for the presence of T790M. All clones 
examined were T790M positive, ruling out the alternative possibility that the observed T790M 
fractional abundance (ddPCR) and VAF (NGS) is due to a mixed population of T790M-positive 
and negative cells. 
 
Supplementary Figure 5. ClonTracer barcode analysis of gefitinib treated PC9 cells. a, 
Schematic of ClonTracer (CT) experimental setup. Three independent barcoded PC9 populations 
were generated (CT-A, CT-B, CT-C) and treated in identical fashion,  b, T790M allele specific 
PCR demonstrates that gefitinib treated PC9 populations are enriched for early resistant T790M 
clones. c, Barcode complexity of vehicle treated (pre-treatment) and gefitinib selected PC9 
populations as determined by next generation sequencing of barcodes. To accomodate the 
barcode complexity observed in vehicle treated groups, top 95% of the total cell population was 
used for estimating the number of unique barcodes. d, Heatmap depicting barcode abundance in 
pre-treatment and gefitinib treated PC9 populations. Note that replicates of the same transduced 
pool exhibit substantial overlap of enriched barcodes, whereas there is negligible overlap of 
barcodes between each of the three independent pools. 
 
Supplementary Figure 6. Emergence of T790M resistant clones from drug tolerant cells. 
a, Intermediate resistant PC9 cells expanded from drug tolerant cells (after 12 weeks gefitinib 
treatment) are negative for T790M by allele specific qPCR. b, A subset of late (fully) gefitinib 
resistant PC9 cells derived from drug tolerant cells acquire T790M. Asterisks denote WZ4002 
sensitivity of T790M positive late resistant cells. c, Fractional abundance of T790M cells can be 
determined by T790M allele specific qPCR. Intermediate freeze-downs of PC9-GR3 cells during 
the development of gefitinib resistance were assayed for the presence of T790M. Red line shows 
gefitinib dose tolerated as a function of time and is replotted from Fig. 1a. Gray bars show 
fraction of T790M cells in population. Inset shows calibration of standard curve. No T790M was 
detected prior to 5 months (threshold for detection 1.5%), where as 6% of population was 
T790M positive at 5.5 months. d. Fraction of T790M cells (red bar) at intermediate time points 
for selected late resistant T790M clones. PC9-GR3 is shown for comparison. The dotted line 
depicting an exponential growth curve fit to the data is shown for illustrative purposes. 
 
Supplementary Figure 7. Assessment of drivere gene amplification in late non-T790M 
resistant clones. Assessment of MET, KRAS, EGFR, HER2, NRAS and BRAF amplification by 
quantitative PCR on genomic DNA from late gefitinib resistant PC9 clones. Copy number 
relative to LINE1 (MET, KRAS, EGFR, HER2, NRAS and BRAF), chromosome 12 (KRAS) or 
chromosome 7 (MET, EGFR, BRAF) was calculated after normalization to MGH1075 (stromal 
fibroblast DNA) diploid control. HCC827-GR6 is MET amplified positive control, H358 is 
KRAS amplified positive control.  
 
Supplementary Figure 8. T790M can emerge from drug tolerant clones. a, No early T790M 
resistant clones were observed after treating ten independent PC9 single cell sub-clones (5,000 
cells/well) with gefitinib for two weeks. e, A subset of gefitinib resistant clones emerging from 
PC9 single cell sub-clone A develop T790M. c, Introduction of pre-existing T790M cells into 
single cell clone populations recapitulates emergence of early resistant clones. An early T790M 
resistant clone (see Fig. 2b) was labeled with RFP to generate PC9-T790M-RFP cells, which 
were spiked into a combined background of unlabeled single cell-derived clonal lines A-D at a 
frequency of 1:10,000. Cells were treated gefitinib and cell viability was measured weekly with 
the RealTime-Glo assay. d, The number of resistant wells that were newly detected at each time 
interval for two independent experiments. b, A cumulative density function modeling the 
emergence of PC9-T790M-RFP clones indicates that 72.6% of emerging pre-existing T790M 
clones are detectable 2 weeks after starting gefitinib treatment. We observed that 4 out of 4 
single cell clone lines yielded late T790M resistant clones. The probability that these late T790M 
clones emerged from undetected pre-existing T790M cells is 0.2744 = 0.006. 
 
Supplementary Figure 9. Estimating growth rate of PC9 drug tolerant cells in the presence 
of gefitinib. a, PC9 pools were treated with 300 nM gefitinib and cell number tracked over time 
using RealTime-Glo assay. The population sizes between weeks 5-10 were used to fit growth 
parameters for mathematical modeling of evolution of T790M from drug tolerant cells (see Fig. 
3c-d). b, Comparison between analytical solution (black squares) and the Monte Carlo 
simulation (red circles) shows very close correlation between predicted frequency of acquiring 
the T790M mutation in drug tolerant cells. The inset compares the correlation between the 
simulation (10,000 runs) and the analytical solution with the calculated theoretical standard error 
range. c, 484 pools of 5000 PC9 cells representing 8 different single cell clonal lines were treated 
with 300 nM gefitinib. By 16 weeks, 203 pools with developing resistance had expanded to 
sufficient numbers to perform T790M genotyping. 3/200 were found to be T790M positive. 
 
Supplementary Figure 10. The MGH119 cell line does not harbor pre-existing T790M cells. 
a, No early resistant colonies emerge from MGH119 cells upon gefitinib treatment. MGH119 
cell pools (5,000/well) were treated with 300 nM gefitinib for three weeks and cell viability 
determined with CellTiter-Glo assay. b, Modeling emergence of pre-existing MGH119 T790M 
clones. MGH119-GR1 cells were labeled with RFP and introduced at low frequency into a 
background of unlabeled MGH119 parental cells. Cells (120 wells, 5,000 cells/well) were treated 
with 300 nM gefitinib and emerging resistant colonies were monitored by RealTime-Glo assay 
and RFP fluorescence. Note that all emerging resistant colonies derive from the introduced RFP-
labeled pre-existing T790M cells. Right panel shows cell viability for all wells (each bar 
represents one well) at 10 weeks. 
 
Supplementary Figure 11. RNA-Seq analysis of PC9 cell populations. a, Proposed 
evolutionary relationship of samples analyzed by RNA-Seq. b, Heatmap of top and bottom 600 
genes contributing most strongly to variance of PC2 demonstrates clustering of  PC9-GR3/drug 
tolerant versus PC9-GR2/parental cells. c, Gene set enrichment analysis (GSEA) was performed 
comparing differentially expressed genes between PC9-GR3/drug tolerant and PC9-
GR2/parental cell groups to Hallmark and Oncogenic Signature gene sets in the Molecular 
Signatures Database (MSigDB). Six gene sets were significantly enriched with a FDR q-value 
less than 0.01. The most significantly enriched gene set correlating with genes upregulated in 
PC9-GR3/drug tolerant was epithelial-to-mesenchymal transition. (EMT-related gene sets are 
highlighted in yellow.) d, Significant enrichment of genes associated with TGF-β induced EMT 
in lung cancer cells (GSE17708) was also observed in PC9-GR3/drug tolerant cells. 
 
Supplementary Figure 12. Drug tolerant cells are characterized by loss of apoptotic 
response despite inhibition of EGFR signaling. a, Gefitinib tolerant PC9 cells have decreased 
apoptotic response to EGFR inhibition. PC9 parental cells were treated with gefitinib for two 
weeks and apoptotic response to 1 µM gefitinib or WZ4002 was determined (PAR = parental 
cells, GEF DT = gefitinib tolerant cells). b, Drug tolerant cells maintain residual pAKT and 
pERK signaling in the presence of gefitinib and have impaired upregulation of BIM.  
 
Supplementary Figure 13. Acquisition of T790M by drug tolerant cells leads to emergence 
of T790M clones with reduced apoptotic sensitivity to WZ4002. a, To model evolution of 
T790M from drug tolerant cells, PC9 cells were treated with 300 nM gefitinib for 4 weeks to 
generate T790M-negative drug tolerant cells. Pools of 1000 drug tolerant cells in 96-well plate 
format were infected with lenti pTREX-DEL19/T790M at a low titer to infect approximately 1 
cell every other well. Cells were treated with doxycycline (DOX) to induce expression of T790M 
and then cultured in the presence of gefitinib. Cell number was assayed weekly using RealTime-
Glo. After approximately 3 weeks, pTREX-DEL19/T790M resistant colonies were detected 
above background drug tolerant cells. Red lines indicate wells with emerging pTREX-
DEL19/T790M clones, black lines indicate wells with only drug tolerant cells. After 30 days, all 
cells were treated with puromycin to distinguish which drug tolerant clones contained the 
pTREX-DEL19/T790M transgene (designated PC9 DT-DEL19/T790M) and to eliminate 
uninfected drug tolerant cells. Nine out of ten clones tested had reduced apoptotic sensitivity to 
WZ4002 compared to PC9 parental cells infected with lenti pTREX-DEL19/T790M (and 
pTREX-DEL19 and pTREX-GFP controls), which represent pre-existing T790M cells (G = 
Gefitinib, W= WZ4002; data are expressed as % apoptosis above vehicle control). b, Western 
blot confirmation of expression of T790M EGFR in three pTREX-DEL19/T790M drug tolerant 
clones. Cells were treated with 1 µM geftinib or WZ4002 for 24 hours. c, Western blot 
confirmation of expression of T790M EGFR in MGH119-pTREX- T790M cells (see Fig. 4b) 
 
Supplementary Figure 14. Rationale for re-analyzing patient-derived cell line combination 
drug screen data. Loss of apoptotic response in PC9-GR3 cells manifests more prominently as a 
change in Emax rather than shift in GI50.   
Methods 
 
Cell lines 
The EGFR mutant NSCLC PC9 cell line (EGFR exon 19 del E746_A750, EGFR amplified) was 
obtained from the MGH Center for Molecular Therapeutics. The identity of PC9 parental, GR2 
and GR3 cell lines were verified by STR analysis (Bio-synthesis, Inc.) at the time that these 
studies were performed. EGFR mutant NSCLC patient-derived cell lines were established in our 
laboratory from core biopsy or pleural effusion samples as previously described14,40. The 
MGH1075 stromal fibroblast line was established in our laboratory from a surgical resection 
specimen of an early stage primary lung adenocarcinoma.  All patients signed informed consent 
for an IRB-approved protocol giving permission for research to be performed on their samples. 
The HCC827-GR6 line (Exon 19 deletion, MET amplified) was previously described6. H358 
cells were obtained from the Center for Molecular Therapeutics at MGH. PC9-T790M-RFP and 
MGH119-GR1-RFP cells were generated by infecting the PC9 Early T-1 clone and MGH119-
GR1 cells, respectively, with Cignal Lenti RFP (Qiagen) lentivirus followed by puromycin 
selection. All cell lines were maintained in RPMI supplemented with 10% FBS, except MGH125 
and MGH138 cells which were maintained in ACL4 with 10% FBS and TCM with 10% FBS, 
respectively. All experiments were performed in RPMI with 10% FBS. All cells were routinely 
tested and verified to be free of mycoplasma contamination. 
 
Antibodies and reagents 
For western blotting, the following antibodies were used: phospho-EGFR Y1068 (Abcam); 
EGFR, pERK1/2 T202/204, ERK1/2, p-AKT S473, Actin (Cell Signaling); AKT1/2/3 (Santa 
Cruz). For cell culture studies, gefitinib, WZ4002, NVP-AEW541, ABT-263 (all from Selleck), 
were dissolved in DMSO to a final concentration of 10 mmol/l and stored at –20°C. Unless 
otherwise specified, 1 µM concentration was used for in vitro cell culture experiments. 
 
In vitro generation of gefitinib resistant cell lines 
Gefitinib resistant PC9-GR2, PC9-GR3 and MGH119-GR1 cells were established by culturing 
parental cells in escalating concentrations of gefitinib (10 nM – 1 µM) as tolerated as previously 
described 14. MGH119-GR2 cells were established by culturing parental cells in full dose 
gefitinib (1 µM). Early, drug tolerant, late PC9 resistant clones were established by culturing in 
300 nM gefitinib until resistant, at which point they were maintained in 1 µM gefitinib. During 
generation of resistance, media and drug were replaced twice per week. 
 
Generation of PC9 single cell sub-clones 
PC9 parental cells were seeded into 96-well plates at a density of 0.5 cells/well. After 2 weeks, 
approximately 25-40% of wells (50-80% of theoretical yield) contained colonies of about 10,000 
cells. A minority of wells contained two colonies, which were easily distinguishable. Wells 
containing only single colonies were expanded an additional 6-10 doublings for use in 
experiments. 
 
PI/Annexin apoptosis assay 
Cells were seeded at low density 24 hours prior to drug addition. 72 hours after adding drugs, 
floating and adherent cells were collected and stained with propidium iodide and Cy5-Annexin V 
(BD Biosciences) and analyzed by flow cytometry. The annexin-positive apoptotic cell fraction 
was analyzed using FloJo software. 
 
CellTiter-Glo proliferation 
For dose response assays, cell lines were seeded into 96-well plates 24 hours before addition of 
drug. Cell proliferation was determined by CellTiter-Glo assay (Promega) 72 hours after adding 
drug using standard protocols. For time course experiments, multiple plates were seeded and 
drugged in identical fashion and at indicated time points plates were frozen at -80oC; all plates in 
an experiment were developed with CellTiter-Glo simultaneously. For early resistant/drug 
tolerant cell experiments, CellTiter-Glo was performed at indicated times on cells in situ. 
 
RealTime-Glo viability assay 
Cell viability was assayed in situ once weekly starting the day after seeding using the RealTime-
Glo assay (Promega) according to the manufacturers protocol. Briefly, MT Cell Viability 
Substrate and NanoLuc Enzyme were diluted 1:500 in media and 25 µl was added to each well 
(1/5 total final volume). Cells were incubated for 1 hour at 37oC and luminescence measured. 
For experiments including RFP-labeled cells, RFP fluorescence was measured using Ex 553 
nm/Em 574 nm. We did not observe any effect of the presence of RFP on RealTime-Glo 
luminescence or vice versa. Fresh media containing gefitinib was replaced immediately after 
each assay. 
 
Long term viability assay 
Long term viability assays were completed by plating 1,000-4,000 cells/well in replicate 96-well 
plates.  Cells were treated in quadruplicate 2x/week and fixed at days 0, 3, 7, 14, 21, 28 and 35 
with a mixture of formaldehyde (1.0%), PBST (0.04%), and Hoecsht dye (1ug/ml).   Stained 
nuclei were imaged and then counted using a Molecular Devices ImageXpress Micro high 
content imager and MetaXpress software. 
 
Cell cycle Analysis 
Cells were seeded 24 hours prior to experiment to give a confluency of 30-50%. Drugs were 
added for 24 hours and cells harvested, stained with propidium iodide and analyzed by flow 
cytometry.  Cell cycle sub-populations were calculated using the FloJo software cell cycle 
module. 
 
JC-1 mitochondrial depolarization assay 
Cells were treated with EGFR inhibitor in the presence of 10 µM QVD-Oph to prevent 
subsequent apoptosis. 48 hours after drug treatment, cells were harvested and stained with JC-1 
(Life Technologies) according to the manufacturers recommendations. 10 µM CCCP was used as 
a positive control. Cells were analyzed by flow cytometry using excitation/emission filters for PE 
and FITC. Mitochondrial depolarization is indicated by a decrease in the red/green fluorescence 
intensity ratio. 
 
Quantitative RT-PCR assay for gene expression 
Cells were seeded 24 hours prior to give a confluency of 50%. Cells were treated with drugs for 
24 hours and RNA was extracted using the RNeasy Kit (Qiagen). cDNA was prepared from 500 
ng total RNA with the First Strand Synthesis Kit (Invitrogen) using oligo-dT primers. 
Quantitative PCR was performed using FastStart Sybr Green (Roche) on a Lightcycler 480. 
mRNA expression relative to ACTIN was calculated using the Delta-Delta threshold cycle 
method. Primers used: DUSP6 F 5’-CGACTGGAACGAGAATACGG-3’, R 5’- 
TTGGAACTTACTGAAGCCACCT-3’; SPRY4 F 5’- CCCCGGCTTCAGGATTTA-3’, R 5’-
CTGCAAACCGCTCAATACAG-3’; HER3 F 5’-CTGATCACCGGCCTCAAT-3’, R 5’-
GGAAGACATTGAGCTTCTCTGG-3’; DAPK1 F 5’-CCCTTGTCCCAGTTGAAGAA-3’, R 
5’-CCGGTCGAGGAACATTCA-3’; BIM F 5'- GATCCTTCCAGTGGGTATTTCTCTT-3', R 
5'-ACTGAGATAGTGGTTGAAGGCCTGG-3; Actin F 5'-CTGTGCTATCCCTGTACGCCTC-
3’, R 5'-CATGATGGAGTTGAAGGTAGTTTCGT-3’; GAPDH F 5'-
AACAGCGACACCCATCCTC-3’, R 5'-CATACCAGGAAATGAGCTTGACAA-3. 
 
T790M quantitative PCR assay 
The T790M mutation was detected using allele specific primers (F) 5’-
ACCATGCGAAGCCACACTGACG-3’ and (R) 5’-AGCCGAAGGGCATGAGCTGGA-3’ in 
conjunction with an EGFR exon 20 Taqman probe 5’-ATCACGTAGGCTTCCTGGAG-3’. A 
commercially available EGFR exon 19 deletion Taqman assay was used as a reference 
(Hs00000228_mu, Life Technologies).  Quantitative PCR was performed on genomic DNA 
using either FastStart PCR Master or Lightcycler 480 Probes Master kits (Roche) on a 
Lightcycler 480. For screening assays, ∆Cp(T790M-DEL19) < 8 was considered positive and 
∆Cp > 10 was considered negative (Probes Master), or ∆Cp < 14 positive/∆Cp > 16 negative 
(FastStart). 
 
EGFR T790M droplet digital PCR analysis 
Isolated gDNA was amplified using ddPCR™ Supermix for Probes (Bio-Rad) with EGFR 
p.T790M (PrimePCR™ ddPCR™ Mutation Assay, Bio-Rad) for point mutation detection. 
ddPCR was performed according to manufacturer’s protocol and the results reported as 
percentage or fractional abundance of mutant DNA alleles to total (mutant plus wild type) DNA 
alleles. 8 to 10 µl of DNA template was added to 10 µl of ddPCR™ Supermix for Probes (Bio-
Rad) and 2 µl of the primer/probe mixture. Droplets were generated using Auto-DG where the 
reaction mix was added together with Droplet Generation Oil for Probes (Bio-Rad). Droplets 
were then transferred to a 96 well plate (Eppendorf) and then thermal cycled with the following 
conditions: 5 minutes at 95°C, 40 cycles of 94°C for 30s, 55°C for 1 minute followed by 98°C 
for 10 minutes (Ramp Rate 2°C/sec). Droplets were analyzed with the QX200™ Droplet Reader 
(Bio-Rad) for fluorescent measurement of FAM and HEX probes. Gating was performed based 
on positive and negative controls, and mutant populations were identified. The ddPCR data were 
analyzed with QuantaSoft analysis software (Bio-Rad) to obtain Fractional Abundance of the 
mutant DNA alleles in the wild-type/normal background. Fractional Abundance is calculated as 
follows: F.A. % = (Nmut/(Nmut+Nwt))*100), where Nmut is number of mutant events and Nwt 
is number of WT events per reaction. ddPCR analysis of normal control (from cell lines) and no 
DNA template controls were always included. Samples with too low positive events were 
repeated at least twice in independent experiments to validate the obtained results.  
 
Clinical cancer genotyping analysis 
DNA was extracted from late non-T790M gefitinib resistant PC9 clones using the DNeasy kit 
(Qiagen). Genotyping was performed using the MGH NGS platform which utilizes a multiplex 
polymerase chain reaction (PCR) technology called Anchored Multiplex PCR (AMP) for single 
nucleotide variant (SNV) and insertion/deletion (indel) detection in genomic DNA using next 
generation sequencing (NGS). Genomic DNA was sheared with the Covaris M220 instrument, 
followed by end-repair, adenylation, and ligation with an adapter.  A sequencing library targeting 
hotspots and exons in 39 genes was generated using two hemi-nested PCR reactions.  Illumina 
MiSeq 2 x 151 base paired-end sequencing results were aligned to the hg19 human genome 
reference using BWA-MEM.  MuTect and a laboratory-developed insertion/deletion analysis 
algorithm were used for SNV and indel variant detection, respectively.  This assay has been 
validated to detect SNV and indel variants at 5% allelic frequency or higher in target regions 
with sufficient read coverage.  Variants are reported with Human Genome Variation Society 
(HGVS) protein and DNA nomenclature, followed by the referenced Ensembl transcript ID. The 
gene targets covered by this assay are as follows (exons): AKT1 (3), ALK (22, 23, 25), APC (16), 
BRAF (11, 15), CDH1 (1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11,12, 13, 14, 15, 16), CDKN2A (1, 2, 3), 
CTNNB1 (3), DDR2 (12, 13, 14, 15, 16, 17, 18), EGFR (7, 15, 18, 19, 20, 21), ERBB2 (10, 20), 
ESR1 (8), FBXW7 (1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11), FGFR1 (4, 8, 15, 17), FGFR2 (7, 9, 12,14), 
FGFR3 (7, 8, 9, 14, 16), FOXL2 (1), GNA11 (5), GNAQ (4, 5), GNAS (6, 7, 8, 9), HRAS (2, 3), 
IDH1 (3, 4), IDH2 (4), KIT (8, 9, 11, 17), KRAS (2, 3, 4, 5), MAP2K1 (2, 3), MET (14, 16, 19, 
21), NOTCH (25, 26, 34), NRAS (2, 3, 4, 5), PDGFRA (12, 14, 18, 23), PIK3CA (2, 5, 8, 10, 
21), PIK3R1 (1, 2, 3, 4, 5, 6, 7, 8, 9, 10), PTEN (1, 2, 3, 4, 5, 6, 7, 8, 9), RET (11, 16), ROS1 
(38), SMAD4 (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12), SMO (9), STK11 (1, 2, 3, 4, 5, 6, 7, 8, 9), TP53 
(1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11), and VHL (1, 2, 3). 
 
Gene amplification quantitative PCR assay 
Quantitative PCR was performed on genomic DNA using FastStart Sybr Green (Roche) on a 
Lightcycler 480. Primers for KRAS, MET, Chromosome 12 control, Chromosome 7 control 
were previously described41. EGFR, BRAF and NRAS primers were adapted from Dias-
Santagata et al42: EGFR F 5'- CCTCCTTCTGCATGGTATTC-3', R 5'- 
GCAGCATGTCAAGATCACAG-3'; BRAF F 5'- TGCTTGCTCTGATAGGAAAATG-3', R 5'- 
CTGATGGGACCCACTCCAT-3'; NRAS F 5'- CAACAGGTTCTTGCTGGTGT-3', R 5'- 
GAGAGACAGGATCAGGTCAGC-3'.   LINE1 primers: F 5’-
AAAGCCGCTCAACTACATGG -3’, R 5’-TGCTTTGAATGCGTCCCAGAG -3’). ∆Cp 
between gene-control (KRAS - Chr.12, LINE1; MET, EGFR, BRAF - Chr. 7, LINE1; HER2, 
NRAS - LINE1) were calculated and normalized to MGH1075 diploid fibroblast control. 
HCC827-GR6 were used as a MET amplification control 6 and H358 cells were used as KRAS 
amplification control.  
 
Generation of Tet-inducible EGFR pTREX cell lines 
Exon 19 del and Exon 19 del/T790M plasmids were purchased from Addgene (32062, 32072). 
EGFR sequences were PCR amplified with the F 5’-CACCATGCGACCCTCCGGGACG-3’ and 
R 5’-TCATGCTCCAATAAATTCACTG-3’ primers and ligated into the pENTR/D-TOPO 
vector using the pENTR Directional TOPO Cloning Kits (Invitrogen). The sequence was then 
introduced into the pTREX vector (kindly provided by Novartis) using Gateway LR Clonase 
Enzyme (Invitrogen). The pTREX-DEL19 and pTREX-DEL/T790M vectors were subsequently 
verified by DNA sequencing. Lentivirus was produced using standard procedures43. PC9 and 
MGH119 cells were infected with lentivirus followed by puromycin selection. Cells were 
cultured in the presence of 10 ng/ml doxycycline to induce expression of EGFR construct. For 
infection of PC9 drug tolerant single cells, cells were infected with a lentiviral titer that yielded a 
single puromycin resistant colony in ~50% of wells. 
 
Mouse xenograft studies 
All mouse studies were conducted through Institutional Animal Care and Use Committee–
approved animal protocols in accordance with institutional guidelines. For xenograft studies, cell 
line suspensions were prepared in 1:10 matrigel and 5x106 cells were injected subcutaneously 
into the flanks of female athymic nude (Nu/Nu) mice (6-8 weeks). Visible tumors developed in 
approximately 2-4 weeks. Tumors were measured with electronic calipers and the tumor volume 
was calculated according to the formula V = 0.52 x L x W2. Mice with established tumors were 
randomized to drug treatment groups using covariate-adaptive randomization to minimize 
differences in baseline tumor volumes: WZ4002 50 mg/kg (10% 1-methyl-2-pyrolidone, 90% 
PEG300), ABT-263 100 mg/kg (30% PEG400/60% Phosal 50 PG/10% ethanol), or 
combinations. Drug treatments were administered by oral gavage and tumor volume measured 
twice weekly as above. For pharmacodynamic studies, mice were sacrificed and tumors removed 
3 hours after drug administration on day 3. Tumors were snap frozen and lysates prepared for 
western blotting. Investigators performing tumor measurements were not blinded to treatment 
group. Sample size (minimum N=7 per treatment group) was chosen to verify satisfactory inter-
animal reproducibility. 
 
ClonTracer barcode library 
Construction of the ClonTracer barcode library and generation of lentiviral particles was 
previously described8. Pools of 10 million PC9 cells were barcoded by lentiviral infection at a 
MOI of 0.1-0.2 and infected cells were selected with puromycin. Infected cell populations were 
expanded in culture for the minimal time period to obtain a sufficient number of cells to set up 
replicate experiments. 20 million cells (~10x barcode representation) were seeded in multiple 
replicate plates and treated with vehicle or 300 nM gefitinib (5 replicates). Vehicle treated cells 
reached confluency within 3 days and the entire pool was pelleted and snap frozen. Gefitinib 
treated plates became confluent from emergence of early resistant clones and were harvested 
after 3 weeks. Cell counts were approximately 20 million cells per replicate plate. Genomic 
DNA was extracted from the frozen cell populations with a QIAamp DNA Blood Maxi Kit 
(Qiagen). We used PCR to amplify the barcode sequence for NGS and introduce Illumina 
adaptors and index sequences8. PCR primer sequence information can be found at 
https://www.addgene.org/pooled-library/clontracer/. The sampling of sufficient template 
coverage was ensured by parallel PCR reactions.  
 PCR-amplified products were sequenced on an Illumina HiSeq2500 sequencer in Rapid 
Mode using the 50 Cycle TruSeq Rapid v2 SBS Kit, TruSeq Rapid SR v2 Cluster Kit, and HiSeq 
Rapid SR v2 Flow Cell (Illumina) as previously described8.. Barcode-composition analysis was 
carried out as previously described8. A barcode was called significant if it was seen at more than 
0.01% of the total population in the drug treated samples (10 times the fraction of the most 
enriched barcode in the vehicle treated replicates). 
 
Cumulative density function modeling of emergence of T790M clones 
Using the cumulative number (N) of RFP+ clones detected at each time point, a best fit model 
(without being highly sensitive to local noise) was calculated with the Matlab Curve Fitting Tool 
with fittype exp2, representing a model of the form a*exp(b*x) + c*exp(d*x). The 95% 
confidence bounds for the coefficients of equation 1 were: a = 53.56 (47.19, 59.93), b = 
0.0002647 (-0.001714, 0.002243), c = -53.58 (-60.17, -47), d = -0.09483 (-0.1178, -0.07186). 
The equation: 
𝑓𝑡=53.56 𝑒.0002647t – 53.58 𝑒−0.09483𝑡 
r2=0.9981 
 
was normalized by the value f(70)=54.492, transforming it into a cumulative density function  
with values ranging from [0,1]:  
53.56 𝑒.0002647t – 53.58 𝑒−0.09483𝑡 
54.492 
The value of the CDF at t(14 days) = 0.7259, representing the probability that a pre-existing 
T790M clone would emerge within 14 days. The probability that a pre-existing T790M would 
not emerge within 14 days is 1-0.7259= 0.2741. The probability of this occurring in 4 
independent trials= 0.2741^4= 0.0056.  
 
Estimation of frequency of pre-existing T790M clones in parental PC9 cell stock 
After 2 weeks of drug exposure, 90 of 1260 wells were detected to contain resistant T790M 
colonies. Based on the above modeling of emergence of pre-existing RFP-labeled T790M clones, 
this represents approximately 72% of pre-existing T790M cells. Thus the theoretical frequency 
of pre-existing T790M can be estimated: 
            (90 colonies/0.7259)       =   0.00001968   ≈  1:50000 
                          1260 wells × 5000 cells/well) 
 
From experiments generating PC9 single cell clones, the efficiency of single PC9 cells to 
establish progeny is between 50-80%, thus the frequency of T790M cells in our parental PC9 
line is approximately 1:25000 – 1:50000.  
 
Mathematical modeling of evolution of T790M from drug tolerant cells 
To model de novo acquisition of the T790M mutation during drug treatment, we assumed 
a branching process27 comprised of N0 drug tolerant cells that divide at a rate b, die at rate d, and 
upon birth, mutate at a rate µ. Acquisition of T790M mutations yields resistant cells divide at a 
rate of br and die at a rate dr. The range of values of the birth and death rates of drug tolerant 
cells were based on single cell parameters reported by Tyson et al.28 and fit to population growth 
rates determined by tracking the growth of pools of PC9 drug tolerant during weeks 5-11 of 
gefitinib treatment (Supplementary Fig. 9a). The average estimated growth rate determined by 
fitting the growth curves to an exponential function from the week with the smallest population, 
which was usually week 6 until week 11, and taking the average was b-d =0.0015±[0.0012]/h. 
Using the inferred growth rate we back extrapolated the initial population size of the drug 
tolerant cells to be on average N0 = 150±23. Once a cell acquired the T790M mutation, the birth 
and death rate of the resulting T790M resistant cells were assumed to have similar rates as PC9 
parental cells in the absence of drug (Tyson et al28 as well as our own unpublished data). 
Currently there are is no agreement on the average mutation per SNV per cell division, and 
estimation ranges from10-11 up to 10-7 for non-hypermutator cells44,45. More recent estimates 
range from 10-10  to 10-8 46, with a slight tendency towards lower values. Of note, the EGFR 
T790M mutation is a change of ACG to ATG generated by spontaneous deamination of 5-
methylcytosine to uracil, which occurs at 18 times greater than the average rate47; furthermore 
the EGFR gene has a rate that is about twice the average rate46 across the genome (MutSigCV48 
estimation output).  Gene amplification can increase the allelic pool in which a mutation can 
arise, and PC9 cells have EGFR gene amplification (10 copies per cell, see Supplementary Fig. 
4b) with a single T790M mutation being sufficient to confer drug resistance. Thus effectively the 
rate of getting a T790M mutation is about 360 times more likely than an average SNV.  
We modeled the process with a Monte Carlo simulation in order to estimate the fraction 
of drug tolerant pools predicted to acquire T790M by16 weeks after beginning drug treatment. 
Conversely, we simulated the fraction of drug tolerant pools predicted to acquire T790M as a 
function of time using fixed parameters. Additionally we derived an analytical approximation to 
the model 
𝑅 = 1 − (1− 𝜇)𝑁0𝑒(𝑏−𝑑)𝑇𝑏−𝑑 𝑏~𝑁0𝑒(𝑏−𝑑)𝑇
𝑏 − 𝑑
𝑏𝜇 
 
where R represent the fraction of PC9 drug tolerant pools that acquire a T790M mutation as a 
function of time (T).  In Supplementary Fig. 9, we compare the results of the analytical solution 
(black line) to the Monte Carlo simulations (red dots) based on 10,000 runs per set of values. 
One can see that they match very well. The logic behind the solution, is to estimate the number 
of birth events during from day 0 to the end of the experiment which is 
𝑁0𝑒
(𝑏−𝑑)𝑇
𝑏 − 𝑑
𝑏 
and calculating the probability of having at least one T790M mutation. One should have in mind 
that the mutation rate in the equation is not the average mutation per SNV per cell division, 
rather 360 times larger, as explained above. It is possible that prior models may not have taken 
this into account, which may explain the differences in the assumed baseline mutational rates 
between our model and prior models (e.g. 10-8-10-7)27.  
 
RNA-Seq analysis 
Total RNA was isolated using the RNeasy Mini Kit (Qiagen). RNA-Seq libraries were 
constructed from polyA-selected RNA using NEBNext Ultra Directional RNA library prep kit 
for Illumina (New England Biolabs) and sequenced on Illumina HiSeq2500 instrument, resulting 
in approximately 34 million reads per sample on average. STAR aligner49 was used to map 
sequencing reads to transcripts in human hg19 reference genome. Read counts for individual 
transcripts were produced with HTSeq-count50, followed by the estimation of expression values 
and detection of differentially expressed transcripts using EdgeR51. Principle component analysis 
(PCA) was performed on the union of differentially expressed transcripts in all samples. We used 
the package for gene-set enrichment analysis (GSEA)52,53 to analyze the enrichment of functional 
gene groups among differentially expressed transcripts. Normalized enrichment score (NES) and 
enrichment plots were calculated based on gene lists ranked by expression ratio between early 
(PC9 parental and PC9-GR2) and late (PC9-GR3 and drug tolerant) stages. 
 
Combination drug screen 
The combination drug screening platform has been described previously14. Briefly, the panel of 
screened compounds was comprised of 76 targeted agents directed against a broad range of 
biologic targets including regulators of growth factor and development signaling pathways, 
apoptosis, transcription and protein folding, and DNA damage. Cells were treated with vehicle or 
varying concentrations screen drugs (10,000-fold range) in the absence or presence of 1 µM 
WZ4002 for 72 hours and cell viability determined by CellTiter-Glo assay. Each dose response 
curve was normalized to cell viability of corresponding vehicle treated cells (with or without 
WZ4002). For each screen drug dose, a ∆E was calculated: 
∆E = 1-(Viability(+WZ)/Viability(-WZ)) 
The means of the three lowest ∆E for all screen drugs were ranked, and screen drugs that scored 
0.80 or lower in at least 2 of 3 cell lines were identified. 
 
Data and Statistical Analysis 
Data were analyzed using GraphPad Prism software (GraphPad Software). Unless otherwise 
specified, data displayed are mean and standard error. Pair-wise comparisons between groups 
(e.g., experimental versus control) were made using paired or unpaired T-tests as appropriate. 
For xenograft pharmacodynamic studies, unequal variance between groups was observed in a 
minority of cases, so Welch correction was performed for all comparisons. For all other 
experiments, variance between comparison groups was verified to be equivalent. P values below 
0.05 were considered to be statistically significant.  
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